Table 3

Medication use in tight-control (n=126) and usual-care (n=126) groups

Week 0Week 12Week 24Week 36Week 52
MedicationUCTCUCTCUCTCUCTCUCTC
MTX mono71 (56%)118 (94%)75 (60%)120 (95%)73 (60%)66 (52%)67 (53%)59 (47%)66 (52%)66 (52%)
SSZ mono44 (35%)34 (27%)32 (25%)30 (24%)1 (1%)29 (23%)1 (1%)
MTX+SSZ4 (3%)9 (7%)48 (38%)12 (10%)38 (30%)12 (10%)31 (25%)
MTX+anti-TNF2 (2%)6 (5%)11 (9%)7 (6%)14 (11%)
Other DMARD mono8 (6%)7 (5%)4 (3%)3 (3%)5 (5%)3 (3%)5 (5%)3 (3%)
Other DMARD combination1 (1%)2 (2%)4 (3%)6 (5%)5 (5%)7 (6%)4 (3%)
Other DMARD anti-TNF2 (2%)1 (1%)
No DMARD3 (4%)8 (4%)6 (5%)5 (4%)4 (3%)5 (5%)7 (6%)6 (5%)
Additional glucocorticosteroidsOrally6 (5%) 010 (8%)25 (20%)16 (13%)19 (15%)15 (12%)15 (12%)15 (12%)15 (12%)
Intramuscular19 (15%)54 (43%)26 (21%)21 (17%)18 (14%)
Intra-articularNANANANANA
  • TNF, tumour necrosis factor; DMARDs, disease modifying antirheumatic drugs; MTX, methotrexate; NA, not available; SSZ, sulphasalazine; TC, tight control; UC, usual care.